wakey wakey mr nasdaq, page-20

data analysis can take a while...but in only 63 patients, it won't be so bad. it really depends on how many actual variables they are collecting, and how long it will take to enter the data and clean it.

after all the data is entered, they will run a simple analysis (kaplan-meier survival curve is most likely) on the main outcome which is PFS. after this, they will then probably start adjusting for various confounding variables, some of the obvious ones being; age, duration of ovarian cancer, 1st or 2nd remission (in the interim results, they chose to stratify/split by this variable instead), concentration of CA125 etc.

i would imagine that once the data is entered, it shouldn't take long to run preliminary analysis for a presentation and release to market. probably closer to 2 weeks for something like this. 1 month maybe for analyses pertinent to a journal publication

the last person received their final dose in october 2012, and patients are supposed to be followed for at least a year, so i'm not sure how they can call these final results...